



EDELIRIS renew and expand medicinal chemistry collaboration with GALAPAGOS

Lyon – February 3rd, 2010 - EDELIRIS announced today that they have renewed and expanded their collaboration with GALAPAGOS. This expansion is based on results obtained from a 2009 collaboration between the two companies involving medicinal chemistry optimization of a natural product.

Multi-FTE resources from Edelris will be dedicated to several Galapagos projects, including natural product hit exploration and heteroaromatic hit-to-lead optimization. The collaboration also includes privileged access for Galapagos to Edelris' original and innovative Keymical Collections™ series.

"Galapagos has assembled one of the largest pipelines in biotech, through our alliances with major pharmas as well as our internal discovery efforts," said Dr.Graham Dixon, SVP Drug Discovery of Galapagos. "Edelris has a talented and dedicated team of scientists helping us to reach our ambitious goals, and we are happy to work with them on several of our projects."

"We are delighted to be collaborating with Galapagos on relevant novel targets," said Dr.Jean-Yves Ortholand, CEO of Edelris. "This collaboration is a prime example of our commitment to provide innovative solutions towards the discovery of valuable small organic molecules for hit finding and lead optimization."

About Galapagos:

Galapagos is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with four clinical and over 40 discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co. and Roche, Galapagos is eligible to receive up to €3 billion (\$4.5 billion) in downstream milestones, plus royalties. With the acquisition of Argenta, Galapagos now has more than 640 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.

About Edelris:

EDELIRIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies worldwide have already recognized the value and specificity of Edelris offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keymical Collections™ and Smart Fragment structures for FBDD.